P2RY12 and cancer: Several families of anti-coagulant drugs that can target different aspects of the coagulation cascade, including thrombosis (aspirin and antagonists of P2Y12 and PARs) and coagulation factors (heparins, factor X inhibitors), have been evaluated in clinical trials as possible adjuvant therapies for cancer patients (Table 1).